Phylo Secures $13.5 Million Seed Funding Led by Andreessen Horowitz and Menlo Ventures

There is a quiet moment before a lab comes alive. Screens glow, data waits, hypotheses pace like fighters in a tunnel. That pause is where Phylo decided to work. Not on louder promises, not on shinier dashboards, but on the friction itself. The seconds, the handoffs, the mental tax scientists pay just to get started. This week, that instinct got validated with $13.5M in seed funding, co-led by Andreessen Horowitz and Menlo Ventures Anthology, with Zetta, Conviction, SV Angel, and Valkyrie stepping into the rhythm.

Phylo did not come out of nowhere. It came out of Stanford, out of Biomni, out of the uncomfortable truth that biology never had an integrated environment worthy of its ambition. Kexin Huang, Ph.D., CEO, and Yuanhao Qu, Ph.D., Co-founder, saw that gap from opposite ends of the same problem. One trained in computer science, one in biology, both allergic to wasted motion. Add scientific co-founders Jure Leskovec, Ph.D., and Le Cong, Ph.D., and you get a founding quartet that understands graphs, genes, systems, and why none of them should live in silos.

Biomni Lab is not trying to sound smart. It is trying to let scientists be smart faster. An integrated biology environment that connects 82 tools, 68 databases, and 100+ software packages into a single flow, driven by natural language and agentic AI. Instead of stitching pipelines together at midnight, researchers ask questions and watch the machinery move. Data flows where it needs to go. Experiments design themselves. Robots listen. Drug candidates get tuned. Biology stops feeling like a pile of tabs and starts behaving like a system.

The signal is already there. 7,000+ labs. 4,300+ organizations. 18 of the top 20 pharma companies quietly putting it to work. Partnerships with Ginkgo Bioworks and Sage Bionetworks. Integrations that pull knowledge from Consensus, COSMIC, and Addgene. This is what happens when you respect the craft enough to remove the clutter instead of selling around it.

Andreessen Horowitz and Menlo Ventures did not back a feature. They backed a belief that the future of biomedical research belongs to tools that think in workflows, not widgets. Advisors like Malay Gandhi, Carolyn Bertozzi, Ph.D., Feng Zhang, Ph.D., and Fabian Theis, Ph.D., do not show up for science projects. They show up when something foundational is being built, quietly, correctly, and with intent.

Congratulations to the entire Phylo team. This round is not about speed for speed’s sake. It is about momentum that compounds, about giving scientists their time back, and about letting biology finally operate at the tempo it deserves.